Dr. Rita Numerof spoke with BioWorld about HHS’ proposal to modify the current drug rebate system and its implications for pharmacy benefits managers.

If Congress is serious about taming drug prices, it needs to look at the PBM business model and consider fundamental changes. The value they create today is really questionable… rebates are a symptom of the problem we’re facing.

Additionally, Numerof shared that Congress should also look at at the entire healthcare enterprise, and not focus solely on drug prices.

Read the full story: Rx drug rebates: Perverse incentive or money saver?